(Q24301274)

hydrogen peroxide catabolic process

GOA release 2020-03-11

1 reference

GOA release 2020-03-11

1 reference

David S Leake

7

0 references

Philippa Talmud

object named as

Philippa J Talmud

8

0 references

author name string

Wai-Man R Wong

1

0 references

Andrew B Gerry

2

0 references

Wendy Putt

3

0 references

Jane L Roberts

4

0 references

Richard B Weinberg

5

0 references

Steve E Humphries

Macrophages require both iron and copper to oxidize low-density lipoprotein in Hanks' balanced salt solution

6

0 references

language of work or name

English

0 references

publication date

June 2007

0 references

published in

Atherosclerosis

0 references

volume

192

0 references

issue

2

0 references

page(s)

266-74

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Activation of lecithin: cholesterol acyltransferase by apolipoproteins E-2, E-3, and A-IV isolated from human plasma

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Role of lipoprotein-copper complex in copper catalyzed-peroxidation of low-density lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

The effect of inhibitors of free radical generating-enzymes on low-density lipoprotein oxidation by macrophages

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Activation of human plasma cholesteryl ester transfer protein by human apolipoprotein A-IV

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Lipoprotein affinity of human apolipoprotein A-IV during cholesterol esterification.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Acidic pH enables caeruloplasmin to catalyse the modification of low-density lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Prooxidant iron and copper, with ferroxidase and xanthine oxidase activities in human atherosclerotic material

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Biologically modified LDL increases the adhesive properties of endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Analysis of the accuracy and implications of simple methods for predicting the secondary structure of globular proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

The role of lipid peroxidation and antioxidants in oxidative modification of LDL.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

A novel polymorphism of apolipoprotein A-IV is the result of an asparagine to serine substitution at residue 127

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Effect of human Apo AIV against lipid peroxidation of very low density lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Human serum, cysteine and histidine inhibit the oxidation of low density lipoprotein less at acidic pH

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Oxidized amino acids: culprits in human atherosclerosis and indicators of oxidative stress

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Copper can promote oxidation of LDL by markedly different mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Inhibition of copper-induced LDL oxidation by vitamin C is associated with decreased copper-binding to LDL and 2-oxo-histidine formation

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Apoptosis in the vasculature: mechanisms and functional importance

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

The oxidative modification of low-density lipoproteins by macrophages

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Stimulation of lipid peroxidation and hydroxyl-radical generation by the contents of human atherosclerotic lesions

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Vitamin E in human low-density lipoprotein. When and how this antioxidant becomes a pro-oxidant

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Evidence for roles of radicals in protein oxidation in advanced human atherosclerotic plaque

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Vitamin E consumption and the risk of coronary disease in women.

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atheroscleros

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Recognition of solubilized apoproteins from delipidated, oxidized low density lipoprotein (LDL) by the acetyl-LDL receptor

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Two polymorphisms for amino acid substitutions in the APOA4 gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

DNA polymorphisms of human apolipoprotein A-IV gene: frequency and effects on lipid, lipoprotein and apolipoprotein levels in a French population

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Apolipoprotein A-IV: a Protein Occurring in Human Mesenteric Lymph Chylomicrons and Free in Plasma. Isolation and Quantification

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Protection against atherogenesis in mice mediated by human apolipoprotein A-IV

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Measurement of 5-hydroxy-2-aminovaleric acid as a specific marker of metal catalysed oxidation of proline and arginine residues of low density lipoprotein apolipoprotein B-100 in human atherosclerotic lesions

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Human apolipoprotein A-IV reduces secretion of proinflammatory cytokines and atherosclerotic effects of a chronic infection mimicked by lipopolysaccharide

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Direct detection and quantification of transition metal ions in human atherosclerotic plaques: evidence for the presence of elevated levels of iron and copper

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Effects of copper and histidine on oxidative modification of low density lipoprotein and its subsequent binding to collagen

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Vitamin C protects human vascular smooth muscle cells against apoptosis induced by moderately oxidized LDL containing high levels of lipid hydroperoxides

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Measurement of copper-binding sites on low density lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Antioxidative and antiatherosclerotic effects of human apolipoprotein A-IV in apolipoprotein E-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Apolipoprotein AIV Gene Variant S347 Is Associated With Increased Risk of Coronary Heart Disease and Lower Plasma Apolipoprotein AIV Levels

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Human intestinal lipoproteins. Studies in chyluric subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Apolipoprotein A-IV inhibits experimental colitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Plasma distribution of apoA-IV in patients with coronary artery disease and healthy controls

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

The APOA4 T347S variant is associated with reduced plasma TAOS in subjects with diabetes mellitus and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Molecular basis for apo A-IV polymorphisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

Continuous monitoring of in vitro oxidation of human low density lipoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.ATHEROSCLEROSIS.2006.07.017

7 January 2021

10.1016/J.ATHEROSCLEROSIS.2006.07.017

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

16945374

1 reference

Consolidated OpenCitations Corpus – April 2017